What are the recommendations for the three‑dose hepatitis B vaccine schedule?

Hepatitis B Three-Dose Vaccine Schedule Recommendations

For most adults and children, the standard three-dose hepatitis B vaccine schedule is administered at 0,1, and 6 months, which provides optimal long-term immunity with geometric mean titers significantly higher than alternative schedules. 1

Standard Three-Dose Schedules by Age Group

Adults (≥20 years)

• Recombivax HB: 10 μg at 0,1, and 6 months 1
• Engerix-B: 20 μg at 0,1, and 6 months 1
• PreHevbrio: 10 μg at 0,1, and 6 months (ACIP-recommended 2022) 1
• Twinrix (HepA-HepB combination): 20 μg at 0,1, and 6 months 1

Children and Adolescents (11-19 years)

• Engerix-B: 10 μg at 0,1, and 6 months 1
• Recombivax HB: 10 μg at 0,1, and 6 months 1

Infants and Young Children (birth through 10 years)

• Standard dose: 10 μg at 0,1, and 6 months 1

Why the 0-1-6 Month Schedule is Superior

The evidence strongly supports the 0-1-6 month schedule over shortened alternatives. Research demonstrates that longer intervals between the second and third doses result in substantially higher antibody titers and better long-term protection 2, 3.

Specifically:

• The 0-1-6 schedule produces seroprotection rates of 85% compared to 64% with a 0-1-3 schedule 3
• Post-vaccination titers are significantly higher: 52 mIU/mL versus 15 mIU/mL with the shortened schedule 3
• A 2-year follow-up study showed the standard 20 μg (0-1-6 month) regimen maintained a 98.31% seroprotection rate with geometric mean concentration of 427.46 mIU/mL, significantly outperforming alternative schedules 2

Special Populations Requiring Modified Schedules

Hemodialysis Patients and Immunocompromised Adults (≥20 years)

• Recombivax HB: 40 μg at 0,1, and 6 months (3-dose series) 1
• Engerix-B: 40 μg (administered as 2 mL) at 0,1,2, and 6 months (4-dose series) 1
• Annual antibody testing required; give booster when anti-HBs falls below 10 mIU/mL 4

Pregnant Women

• Use only Engerix-B, Recombivax HB, or Twinrix 1
• Avoid Heplisav-B and PreHevbrio due to insufficient pregnancy safety data 1

High-Risk Exposure Situations (Post-exposure, neonates of HBsAg+ mothers)

• Accelerated schedule: 0,1,2, and 12 months can be used 4
• Must include hepatitis B immune globulin (HBIG) for known exposures 4
• The fourth dose at 12 months is essential for long-term protection 5

Critical Timing Requirements for Interrupted Series

If the three-dose series is interrupted, do NOT restart—simply continue where you left off 1. However, maintain these minimum intervals:

• Minimum interval between doses 1 and 2: 4 weeks 1
• Minimum interval between doses 2 and 3: 8 weeks 1
• Minimum interval between doses 1 and 3: 16 weeks 1
• Doses given ≤4 days before the minimum interval are considered valid 1

If only the third dose is delayed, administer it as soon as possible without restarting the series 1.

Common Pitfalls to Avoid

1. Gluteal injection: Never administer in the gluteal region—this results in suboptimal response 4. Use the deltoid in adults or anterolateral thigh in infants.

2. Shortened schedules without completion: While 0-1-2 month schedules provide faster initial seroconversion, they require a fourth dose at 12 months to achieve comparable long-term protection 5. Without this fourth dose, protection is inadequate.

3. Age-related dosing errors: Adolescents aged 11-15 can receive a 2-dose Recombivax HB schedule (10 μg at 0 and 4-6 months), but if they turn 16 before the second dose, switch to the 3-dose series 1.

4. Assuming all vaccines are interchangeable: While hepatitis B vaccines are generally interchangeable, Heplisav-B (2-dose schedule at 0 and 1 month) is NOT approved for hemodialysis patients or pregnant women 1.

Alternative Extended Schedule

For children and adolescents where an extended schedule is acceptable based on low immediate exposure risk, a 0,12, and 24-month schedule can be used 4, 6. This produces seroprotection rates of 88.8% before the third dose and >98% one month after completion, though with slightly lower geometric mean titers (3,159 mIU/mL) compared to the standard schedule (5,687 mIU/mL) 6.

Age and Response Considerations

Younger age (<40 years) is strongly associated with better vaccine response 3. Adults over 40 years produce lower antibody titers (GMT 610 mIU/mL) compared to younger adults 4. Body mass index correlates inversely with final antibody concentration 6. These factors don't change the recommended schedule but may influence decisions about post-vaccination serologic testing in high-risk individuals.